Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Tang H, Leung L, Saturno G, Viros A, Smith D, Leva GD, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R.

Nat Commun. 2019 Jul 18;10(1):3151. doi: 10.1038/s41467-019-11220-x.

2.

Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.

Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E.

Eur Urol Oncol. 2019 Feb;2(1):1-11. doi: 10.1016/j.euo.2018.08.005. Epub 2018 Sep 5.

3.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048.

PMID:
30838379
4.

Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.

Trucco LD, Mundra PA, Hogan K, Garcia-Martinez P, Viros A, Mandal AK, Macagno N, Gaudy-Marqueste C, Allan D, Baenke F, Cook M, McManus C, Sanchez-Laorden B, Dhomen N, Marais R.

Nat Med. 2019 Feb;25(2):350. doi: 10.1038/s41591-018-0325-y.

PMID:
30560902
5.

Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.

Trucco LD, Mundra PA, Hogan K, Garcia-Martinez P, Viros A, Mandal AK, Macagno N, Gaudy-Marqueste C, Allan D, Baenke F, Cook M, McManus C, Sanchez-Laorden B, Dhomen N, Marais R.

Nat Med. 2019 Feb;25(2):221-224. doi: 10.1038/s41591-018-0265-6. Epub 2018 Dec 3. Erratum in: Nat Med. 2018 Dec 18;:.

PMID:
30510256
6.

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC, Marais R.

Eur J Cancer. 2018 Jan;88:1-9. doi: 10.1016/j.ejca.2017.10.029. Epub 2017 Nov 23.

7.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

8.

New insights into naevoid melanomas: a clinicopathological reassessment.

Cook MG, Massi D, Blokx WAM, Van den Oord J, Koljenović S, De Giorgi V, Kissin E, Grant M, Mandal A, Gremel G, Gaudy C, Viros A, Dhomen N, Khosrotehrani K, Marais R, Green AC, Mihm MC Jr.

Histopathology. 2017 Dec;71(6):943-950. doi: 10.1111/his.13317. Epub 2017 Oct 2.

PMID:
28741688
9.

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Tang H, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R.

Nat Commun. 2017 Apr 18;8:14909. doi: 10.1038/ncomms14909. Erratum in: Nat Commun. 2019 Jul 18;10(1):3151.

10.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R.

Ann Oncol. 2016 Oct;27(10):1959-65. doi: 10.1093/annonc/mdw278. Epub 2016 Aug 8.

11.

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.

Korfi K, Smith M, Swan J, Somervaille TC, Dhomen N, Marais R.

Cell Death Dis. 2016 Apr 7;7:e2177. doi: 10.1038/cddis.2016.70.

12.

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, Baenke F, Pedersen M, Rogan J, Swan J, Smith M, Fusi A, Oudit D, Dhomen N, Brady G, Lorigan P, Dive C, Marais R.

Cancer Discov. 2016 Mar;6(3):286-99. doi: 10.1158/2159-8290.CD-15-1336. Epub 2015 Dec 29.

13.

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells.

Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, Viros A, Martin M, Galbraith L, Girotti MR, Dhomen N, Gottlieb E, Marais R.

Mol Oncol. 2016 Jan;10(1):73-84. doi: 10.1016/j.molonc.2015.08.003. Epub 2015 Aug 20.

14.

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C.

Cancer Discov. 2014 Oct;4(10):1214-1229. doi: 10.1158/2159-8290.CD-13-1007.

15.

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.

Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R.

Nature. 2014 Jul 24;511(7510):478-482. doi: 10.1038/nature13298. Epub 2014 Jun 11.

16.

Therapeutic targeting of the epidermal growth factor receptor in human cancer.

Dhomen NS, Mariadason J, Tebbutt N, Scott AM.

Crit Rev Oncog. 2012;17(1):31-50. Review.

PMID:
22471663
17.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

18.

KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor.

Matin RN, Gonzalez D, Thompson L, Lambert SR, Bakr F, Dhomen N, Marais R, McGregor JM, Szlosarek P, Cerio R, Harwood CA.

Am J Clin Dermatol. 2012 Feb 1;13(1):64-5. doi: 10.2165/11593910-000000000-00000. No abstract available.

PMID:
22175303
19.

(V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis.

Rae J, Viros A, Hayward R, Bennett DC, Dhomen N, Longley BJ, Reis-Filho JS, Marais R.

J Invest Dermatol. 2012 Feb;132(2):488-91. doi: 10.1038/jid.2011.341. Epub 2011 Nov 24. No abstract available.

20.

A mouse model of melanoma driven by oncogenic KRAS.

Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, Marais R.

Cancer Res. 2010 Jul 1;70(13):5549-57. doi: 10.1158/0008-5472.CAN-09-4254. Epub 2010 Jun 1.

21.

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.

Cell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040.

22.

Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality.

Dhomen N, Da Rocha Dias S, Hayward R, Ogilvie L, Hedley D, Delmas V, McCarthy A, Henderson D, Springer CJ, Pritchard C, Larue L, Marais R.

Pigment Cell Melanoma Res. 2010 Feb;23(1):112-20. doi: 10.1111/j.1755-148X.2009.00662.x. Epub 2009 Dec 11. Erratum in: Pigment Cell Melanoma Res. 2010 Apr;23(2):302.

PMID:
20002887
23.

BRAF signaling and targeted therapies in melanoma.

Dhomen N, Marais R.

Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix. doi: 10.1016/j.hoc.2009.04.001. Review.

PMID:
19464601
24.

Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R.

Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.

25.

Isolation and characterisation of neural progenitor cells from the adult Chx10(orJ/orJ) central neural retina.

Kokkinopoulos I, Pearson RA, Macneil A, Dhomen NS, MacLaren RE, Ali RR, Sowden JC.

Mol Cell Neurosci. 2008 Jul;38(3):359-73. doi: 10.1016/j.mcn.2008.03.008. Epub 2008 Apr 10.

PMID:
18514541
26.

New insight into BRAF mutations in cancer.

Dhomen N, Marais R.

Curr Opin Genet Dev. 2007 Feb;17(1):31-9. Review.

PMID:
17208430
27.

Absence of chx10 causes neural progenitors to persist in the adult retina.

Dhomen NS, Balaggan KS, Pearson RA, Bainbridge JW, Levine EM, Ali RR, Sowden JC.

Invest Ophthalmol Vis Sci. 2006 Jan;47(1):386-96.

28.

Delayed expression of the Crx gene and photoreceptor development in the Chx10-deficient retina.

Rutherford AD, Dhomen N, Smith HK, Sowden JC.

Invest Ophthalmol Vis Sci. 2004 Feb;45(2):375-84.

PMID:
14744875
29.

Derepression of HMGA2 gene expression in retinoblastoma is associated with cell proliferation.

Chau KY, Manfioletti G, Cheung-Chau KW, Fusco A, Dhomen N, Sowden JC, Sasabe T, Mukai S, Ono SJ.

Mol Med. 2003 May-Aug;9(5-8):154-65.

Supplemental Content

Loading ...
Support Center